We provide you with 20 years of free, institutional-grade data for TCON stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of TCON. Explore the full financial landscape of TCON stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about TCON stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
TRACON Pharmaceuticals, Inc(NASDAQ:TCON) 
TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and age-related macular degeneration and fibrotic diseases in the United States. Its lead clinical stage product include envafolimab (KN035), an inves...
Website: http://www.traconpharma.com
Founded: 2004
Full Time Employees: 19
Sector: Healthcare
Industry: Biotechnology